Study of JMKX003142 Injection in Chinese Healthy Subjects

Phase 1 Unknown 78 enrolled Jemincare Zhejiang Hangyu Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JMKX003142 Injection Administered Randomly, Double-blind, Placebo-controlled, Single-ascending Dose and Multiple-ascending Doses in Chinese Healthy Adult Subjects

Timeline

Start: 2024-04-10
Primary completion: 2025-01-31
Completion: 2025-05-30

Publications

Cui C, Zhu J, Liu Z, Liu J, Huang X, Liu Y, Hu J, Zhang L, Zhang X, Sha Y, Liu D, Li H. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Administration JMKX003142 in Chinese Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Single, and Multiple Ascending Dose Phase I Clinical Trial. Drug Des Devel Ther. 2026 Mar 5;20:583445. doi: 10.2147/DDDT.S583445. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JMKX003142	Unknown	—	Intravenous

Indications

No indication recorded.